Collectively, therefore, CCR5-targeted therapy will be an effective treatment for patients with cancers that express high levels of CCR5/CCL5 and high levels of circulating tumor cells and/or metastases, and may be well positioned to augment the efficacy of current therapies. This evidence concerns the gene CCL5 and neoplasm.